The patient should meet the following criteria to get Wegovy coverage for cardiovascular risk reduction: Initial therapy: Wegovy is prescribed to reduce the risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke in an adult with established cardiovascular disease who is also overweight or obese, and
VAL itself is made up of several databases linkable with the unique identifiers of each patient, and these databases contain individual-level data on age, sex, dispensed prescription drugs, diagnoses, hospitalizations, healthcare consultations, economic transactions, as well as migration and death
Retatrutide is approaching these results without surgery
They tell your body to perform specific functions, such as releasing hormones, reducing inflammation, or stimulating muscle growth